Myasthenia Gravis

Myasthenia gravis (MG) is classified within a group of neurological disorders characterized by impaired signal transmission between nerves and muscles, leading to significant muscle fatigue. These conditions are collectively known as neuromuscular transmission disorders or myasthenic syndromes. MG is a non-hereditary autoimmune disease in which there is a dysfunction at the motor endplate of skeletal muscle, the exact cause of which remains not fully understood. The clinical presentation of myasthenia gravis is marked by muscle weakness that is dependent on exertion. This weakness often affects the aforementioned muscles asymmetrically and can impact single or multiple muscles, irrespective of the side of the body. antibodies-online offers antibodies and proteins for key MG targets which support development of novelle therapeutics.

What is Myasthenia Gravis?

MG is an autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue. The disease is primarily caused by autoantibodies targeting components of the neuromuscular junction, notably the acetylcholine receptor (AChR) and muscle-specific kinase (MuSK). The pathophysiology of MG involves a complex interplay of genetic predisposition and environmental factors, leading to an aberrant immune response.

What Antigens are Involved in Myasthenia Gravis Pathogenesis?

Key targets in MG are the nicotinic acetylcholine receptors (CHRN), which are targeted by autoantibodies. The autoantibodies lead to receptor internalization and complement-mediated damage. Search for other pathogenic antigens has detected antibodies against the muscle-specific tyrosine kinase MuSK and low-density lipoprotein-related protein 4 (Lrp4), both causing pre- and post-synaptic impairments. The muscle membrane-bound protein agrin (heparin sulfate proteoglycan) is considered as fourth pathogen however its role is not fully understood yet.

Human Leukocyte Antigen Targets in MG

The HLA system is crucial for immune function, and specific HLA alleles are involved in presenting autoantigens to the immune system, leading to the activation of autoreactive T cells. These activated T cells can then help B cells produce autoantibodies against components of the neuromuscular junction, such as the acetylcholine receptor or muscle-specific kinase. HLA-DRB1*03:01 for example presents autoantigens to CD4+ T cells, facilitating an autoimmune response against AChR. Similar to HLA-DRB1*03:01, HLA-DRB1*16: helps in presenting autoantigens to T cells, promoting autoimmunity in MuSK-positive MG. HLA-DQB1*05:02: helps in presenting autoantigens related to MuSK, thus contributing to the autoimmune response in these patients.

Therapeutic Approaches for MG

Current therapeutic interventions for MG range from symptomatic treatments to immunomodulatory therapies. Symptomatic treatments, such as acetylcholinesterase inhibitors, enhance neuromuscular transmission by increasing the availability of acetylcholine at the neuromuscular junction. Immunomodulatory therapies include corticosteroids and other immunosuppressants, which reduce overall immune activity. Recently, targeted therapies that interfere with the autoimmune response have gained prominence. Emerging therapies specifically targeting FcRn, such as efgartigimod and rozanolixizumab, represent a novel approach in MG management. These agents are designed to decrease pathogenic IgG levels by blocking FcRn, thereby facilitating the degradation of IgG and reducing autoantibody-mediated pathogenicity.

Another notable approach to combat MG is eculizumab, a monoclonal antibody that inhibits complement activation and prevents damage to the neuromuscular junction. The production of these biotherapeutics involves sophisticated techniques, including recombinant DNA technology and cell culture systems to ensure high specificity and efficacy. The manufacturing process for FcRn inhibitors typically involves the expression of the therapeutic protein in mammalian cell lines, followed by purification and formulation to meet regulatory standards for clinical use.

Available Biosimilar Antibodies for MG Targets

In conclusion, advancing our understanding of the immunological underpinnings of MG and leveraging this knowledge to develop targeted therapeutics is paramount. Continued research into the specific antigens and immune interactions involved in MG will facilitate the development of next-generation therapies that can improve patient outcomes and quality of life.

Julian Pampel, BSc

Content Manager at antibodies-online.com

Creative mind of antibodies-online with a keen eye for details. Proficient in the field of life-science with a passion for plant biotechnology and clinical study design. Responsible for illustrated and written content at antibodies-online as well as supervision of the antibodies-online scholarship program.

Go to author page